Sorafenib
Malignant Solid Neoplasms
Centre Leon BerardSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Malignant Solid Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib Centre Leon Berard | Phase 2 | CCC |
Nilotinib Centre Leon Berard | Phase 2 | CCC |
Durvalumab Centre Leon Berard | Phase 2 | CCC |
Everolimus Centre Leon Berard | Phase 2 | CCC |
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Centre Leon Berard | Phase 2 | CCC |
gw786034 Centre Leon Berard | Phase 2 | CCC |
Lapatinib Centre Leon Berard | Phase 2 | CCC |
Same molecule, other indications
Sorafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →